MapLight Therapeutics, Inc. 13D

Novo Holdings A/S cut its MapLight Therapeutics stake below 5% through sizeable open-market sales and signals no activist intentions.

Novo Holdings A/S, which now beneficially owns 2,086,622 shares or approximately 4.9% of MapLight Therapeutics, Inc.’s common stock, filed this Schedule 13D amendment to disclose substantial open-market sales on July 30, 2026 that reduced its holdings below the 5% reporting threshold; the filing does not indicate any activist agenda or plans to influence management or strategy, and the stake appears to be a passive financial investment with recent trimming rather than a platform for engagement.

Filing Facts

CIK

1770069

Ticker

MPLT

Form

13D

Source Type

fda

Accession

0001388325-26-000034

Alert Tier

8